Severe adverse events from treatment with genetically engineered biological agents in patients with rheumatic diseases

Terapevticheskii Arkhiv

Volumn 85, Issue 5, 2013, Pages 37-43

  Moiseev, S V ^a   Novikov, P I ^a   Semenkova, E N ^a   Strizhakov, L A ^a   Gulyaev, S V ^a   Yanushkevich, T N ^a   Nikiforova, N V ^a   Meshkov, A D ^a   Panasyuk, V V ^a   Sokorin, Yu D ^a   Taranova, M V ^a   Parfenova, S A ^a   Dubrovskaya, L V ^a   Zhabina, E S ^a   Kuznetsova, E I ^a   Lopatina, I A ^a   Bulanov, N M ^a   Mukhin, N A ^a  

^a I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Efficiency; Genetically engineered biological agents; Rheumatic diseases; Rheumatoid arthritis; Safety; Systemic lupus erythematosus; Vasculitis

Indexed keywords

IMMUNOLOGIC FACTOR; INFLIXIMAB; MONOCLONAL ANTIBODY; RITUXIMAB;

ADULT; ANCA ASSOCIATED VASCULITIS; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENETIC ENGINEERING; HUMAN; MALE; METHODOLOGY; PATHOPHYSIOLOGY; REMISSION; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SEVERITY OF ILLNESS INDEX; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ADULT; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ARTHRITIS, RHEUMATOID; FEMALE; GENETIC ENGINEERING; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; REMISSION INDUCTION; RHEUMATIC DISEASES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84880497612     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Ducharme J., Pelletier C, Zacharias R. The safety of infliximab infusions in the community setting. Can J Gastroenterol 2010; 24 (5)307-311.
2. van Vollenhoven R., Emery P., Bingham C. et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 2010; 37 (3): 558-567.
3. Herndndez-Cruz B., Garcta-Arias M., Ariza Ariza R., Martin Mola E. [Rituximab in rheumatoid arthritis: a systematic review of efficacy and safety]. Reumatol Clin 2011; 7 (5): 314-322.
4. Leombruno J., Einarson T., Keystone E. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009; 68 (7): 1136-1145.
5. Curtis J., Jain A., Ashling J. et al. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum 2010; 40: 2-14.
6. Listing J., Strangfeld A., Kary S. et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 3403-3412.
7. Askling J., Fored C, Brandt L. et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007; 66: 1339-1344.
8. Curtis J., Xie E, Chen L. et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis 2011; 70 (8): 1401-1406.
9. Salliot C, Dougados M., Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009; 68: 25-32.
10. Rigal E., Gateault P., Lebranchu Y., Hoarau C. [Therapeutic monoclonal antibodies: update on the risk of opportunistic infections]. Med Sci (Paris) 2009; 25 (12): 1135-1140.
11. Singh J., Wells G., Christensen R. et al. Adverse effects of biologies: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011; 16 (2): CD008794.
12. Keane J., Gershon S., Wise R. Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent. N Engl J Med 2001; 345: 1098-1104.
13. Ambrosioni J., Lew D., Garbino J. Nocardiosis: updated clinical review and experience at a tertiary center. Infection 2010; 38 (2): 89-97.
14. Diaz-Lagares C, Perez-Alvarex R., Garcia-Hernandez F.J. et al. Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthr Res Ther 2011; 13: R112.
15. Tony H.-R, Burmester G, Schulze-Koops H. et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthr Res Ther 2011; 13:R75.
16. Furie R., Looney R., Rovin B. et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study. Arthritis Rheum 2009; 60 (Suppl. 10): 1149.
17. Merrill J., Neuwelt C, Wallace D. et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-233.
18. Jones R., Ferraro A., Chaudhry A. et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60: 2156-2168.
19. Tesfa D., Ajeganova S., Hagglund H. et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum 2011; 63 (8): 2209-2214.
20. Jones R., Ferraro A., Chaudhry A. et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60 (7): 2156-2168.